YNT-185 HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461992

CAS#: 1804978-82-2 (HCl)

Description: YNT 185 is a potent and selective OX2 agonist. YNT-185 suppressed cataplexy-like episodes in orexin knockout and orexin neuron-ablated mice, but not in orexin receptor-deficient mice.


Chemical Structure

img
YNT-185 HCl
CAS# 1804978-82-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 461992
Name: YNT-185 HCl
CAS#: 1804978-82-2 (HCl)
Chemical Formula: C33H39Cl2N5O5S
Exact Mass: 687.2049
Molecular Weight: 688.665
Elemental Analysis: C, 57.56; H, 5.71; Cl, 10.30; N, 10.17; O, 11.62; S, 4.66

Price and Availability

Size Price Availability Quantity
10.0mg USD 465.0 2 Weeks
Bulk inquiry

Related CAS #: 804978-81-1 (free base)   1804978-82-2 (HCl)    

Synonym: YNT 185; YNT185; YNT-185; YNT-185 HCl; YNT-185 hydrochloride;

IUPAC/Chemical Name: 3'-[[[3-[[2-[[2-(Dimethylamino)benzoyl]amino]ethyl]amino]phenyl]amino]sulfonyl]-4'-methoxy-N,N-dimethyl-[1,1'-biphenyl]-3-carboxamide dihydrochloride

InChi Key: AIORBDHFHVKRIY-UHFFFAOYSA-N

InChi Code: InChI=1S/C33H37N5O5S.2ClH/c1-37(2)29-15-7-6-14-28(29)32(39)35-19-18-34-26-12-9-13-27(22-26)36-44(41,42)31-21-24(16-17-30(31)43-5)23-10-8-11-25(20-23)33(40)38(3)4;;/h6-17,20-22,34,36H,18-19H2,1-5H3,(H,35,39);2*1H

SMILES Code: O=C(C1=CC(C2=CC=C(OC)C(S(=O)(NC3=CC=CC(NCCNC(C4=CC=CC=C4N(C)C)=O)=C3)=O)=C2)=CC=C1)N(C)C.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 688.665 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018 Apr;27(4):389-406. doi: 10.1080/13543784.2018.1459561. Epub 2018 Apr 9.Review. PubMed PMID: 29623725.

2: Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017 May 30;114(22):5731-5736. doi: 10.1073/pnas.1700499114. Epub 2017 May 15. PubMed PMID: 28507129; PubMed Central PMCID: PMC5465922.

3: Irukayama-Tomobe Y, Yanagisawa M. [Development of a Therapeutic Drug for Narcolepsy]. Brain Nerve. 2018 Nov;70(11):1255-1263. doi: 10.11477/mf.1416201171. Japanese. PubMed PMID: 30416119.

4: Toyama S, Shimoyama N, Tagaito Y, Nagase H, Saitoh T, Yanagisawa M, Shimoyama M. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats. Anesthesiology. 2018 May;128(5):992-1003. doi: 10.1097/ALN.0000000000002161. PubMed PMID: 29521652.

5: Liu X, Yang R, Bai W, Xu X, Bi F, Zhu M, Dou X, Li H. Exploring the role of orexin B-sirtuin 1-HIF-1α in diabetes-mellitus induced vascular endothelial dysfunction and associated myocardial injury in rats. Life Sci. 2019 Nov 9:117041. doi: 10.1016/j.lfs.2019.117041. [Epub ahead of print] PubMed PMID: 31715188.

6: Yamamoto K, Okui R, Yamatodani A. Activation of orexinergic and histaminergic pathway involved in therapeutic effect of histamine H(4) receptor antagonist against cisplatin-induced anorexia in mice. Naunyn Schmiedebergs Arch Pharmacol. 2019 Aug;392(8):925-936. doi: 10.1007/s00210-019-01646-x. Epub 2019 Mar 27. PubMed PMID: 30919010.